AATS happens to be developing its next set of recommendations, including the AATS risk calculator, slated for discharge in 2014. The agreement is as well as the partnership between the two companies announced in September 2010 where Reata granted to Abbott unique rights to develop and commercialize its lead Goal compound, bardoxolone methyl, outside of the United States, excluding certain Asian marketplaces. The collaboration announced today can be a worldwide agreement and includes a large number of molecules in a broad range of therapeutic areas, including pulmonary, central nervous system disorders and immunology.Aegis will provide the hospitals proprietary equipment and an employer relations expert housed on each medical center campus to help make this happen. Using data gathered through personal wellness profiles, at-risk employees shall be matched with appropriate early detection, education and prevention initiatives offered by the hospitals. With an increased focus on health improvement nationally, a lot more hospitals are taking the lead in enhancing the fitness of their local communities, said Henry Ross, CEO of Aegis.